Bloodstream infections in liver transplant recipients receiving tacrolimus.
The microbial origin, timing, risk factors, and outcome of bloodstream infections (bacteremia and fungemia) were prospectively analyzed in 130 consecutive liver transplant recipients receiving tacrolimus-based immunosuppression; median followup was 3 yr. 22% (29/130) of the patients developed 36 episodes of bloodstream infections (0.28 episodes/patient). Bloodstream infections accounted for 36% (36/100) of all major infections. 81% (29/36) of bloodstream infections were due to bacteremia and 19% (7/36) due to fungemia (candidemia 14% and cryptococcemia 5%). Intravascular catheters were the most frequent source and methicillin-resistant Staphylococcus aureus was the most frequent pathogen causing bloodstream infections. 70% of the catheter related and all bacteremias due to intra-abdominal infections occurred < or = 90 d, whereas 75% of the bacteremias due to biliary source occurred > 90 d after transplantation. Length of initial post-transplant intensive care unit stay (p = 0.014) and readmission to the intensive care unit (p = 0.003) were independently significant predictors of bloodstream infections. 40% of the candidemias occurred within 30 d of transplantation and were of unknown portal, whereas the portal in all candidemias occurring > 30 d post-transplant was known (catheter, hepatic abscess, urinary tract). Mortality in patients with bloodstream infections was 52% (15/29) vs. 9% (9/101) in patients without bloodstream infections (p = 0.0001). In conclusion, intravascular catheters (and not intra-abdominal infections) have emerged as the most common source of bloodstream infections, and gram-positive cocci (S. aureus) as the predominant pathogens in bloodstream infections after liver transplantation.
Singh
N
N
VA Medical Center, Infectious Disease Section, Pittsburgh, PA 15240, USA.
Gayowski
T
T
Wagener
M M
MM
Marino
I R
IR
D000005:Abdomen / Q000382:microbiology; D000328:Adult; D000368:Aged; D016470:Bacteremia / Q000209:etiology*; D001659:Biliary Tract / Q000382:microbiology; D002177:Candidiasis / Q000209:etiology; D002406:Catheterization, Peripheral / Q000009:adverse effects / Q000295:instrumentation; D003422:Critical Care; D003453:Cryptococcosis / Q000209:etiology; D004866:Equipment Contamination; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D016469:Fungemia / Q000209:etiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007902:Length of Stay; D008100:Liver Abscess / Q000382:microbiology; D016031:Liver Transplantation / Q000009:adverse effects; D008297:Male; D016106:Methicillin Resistance; D008875:Middle Aged; D010359:Patient Readmission; D011446:Prospective Studies; D012307:Risk Factors; D013203:Staphylococcal Infections / Q000209:etiology; D013211:Staphylococcus aureus / Q000187:drug effects; D015996:Survival Rate; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000382:microbiology
D007166:Immunosuppressive Agents; D016559:Tacrolimus